[go: up one dir, main page]

WO2004069145A3 - Anticancer compounds, process for their preparation and pharmaceutical compositions containing them - Google Patents

Anticancer compounds, process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2004069145A3
WO2004069145A3 PCT/IB2004/000299 IB2004000299W WO2004069145A3 WO 2004069145 A3 WO2004069145 A3 WO 2004069145A3 IB 2004000299 W IB2004000299 W IB 2004000299W WO 2004069145 A3 WO2004069145 A3 WO 2004069145A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
preparation
pharmaceutical compositions
pharmaceutically acceptable
anticancer compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/000299
Other languages
French (fr)
Other versions
WO2004069145A2 (en
Inventor
Manohar Sharma Vedula
Venkata Adiseshu Kattuboina
Javed Iqbal
Rajagopalan Ramanujam
Sriram Rajagopal
Naga Venkata Srinivasa Mamidi
Ramanatham Josyula
Madhusudhan Gutta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of WO2004069145A2 publication Critical patent/WO2004069145A2/en
Publication of WO2004069145A3 publication Critical patent/WO2004069145A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel anticancer agents, their pharmaceutically acceptable salts, their geometrical isomers and their pharmaceutically acceptable compositions containing them. the present invention more particularly relates to novel quinazoline compounds, their pharmaceutically acceptable salts and their pharmaceutically acceptable compositions containing them. the novel quinazoline compounds have the general formula (I), where all symbols are as defined in the specification.
PCT/IB2004/000299 2003-02-07 2004-02-06 Anticancer compounds, process for their preparation and pharmaceutical compositions containing them Ceased WO2004069145A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN108/MAS/2003 2003-02-07
IN108MA2003 2003-02-07

Publications (2)

Publication Number Publication Date
WO2004069145A2 WO2004069145A2 (en) 2004-08-19
WO2004069145A3 true WO2004069145A3 (en) 2004-12-16

Family

ID=32843816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000299 Ceased WO2004069145A2 (en) 2003-02-07 2004-02-06 Anticancer compounds, process for their preparation and pharmaceutical compositions containing them

Country Status (1)

Country Link
WO (1) WO2004069145A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2431843T3 (en) 2005-02-23 2013-11-28 Shionogi & Co., Ltd. Quinazoline derivative that has tyrosine kinase inhibitory activity
LT3575288T (en) 2009-09-03 2021-12-10 Bristol-Myers Squibb Company QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015118A1 (en) * 1994-11-12 1996-05-23 Zeneca Limited Aniline derivatives
WO2002036570A1 (en) * 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015118A1 (en) * 1994-11-12 1996-05-23 Zeneca Limited Aniline derivatives
WO2002036570A1 (en) * 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
WO2004069145A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2005082892A3 (en) Triazole compounds as antibacterial agents and pharmaceutical compositions containing them
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
GB0114286D0 (en) Nucleoside Derivatives
WO2004074244A3 (en) Pyrimidine compounds
CA2499330A1 (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
TW200612892A (en) Novel compounds
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2006034154A3 (en) Salts of 5-azacytidine
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
WO2004112719A8 (en) Chemical compounds
WO2003095455A3 (en) Substituted pyrazolopyrimidines
TW200616995A (en) Novel compounds
WO2006114520A3 (en) Substituted pyrrolo-pyridines, composition containing them, method for their producing and use thereof
WO2006008028A8 (en) Novel 6-formyltetrahydropteridines method for production and use thereof as medicament against cancer amongst other things
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
MY147262A (en) 1-aza-bicyclo[3.3.1]nonanes
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
WO2004106322A3 (en) Polymorphs of aripiprazole
TW200639156A (en) New compounds
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
WO2004106307A3 (en) Novel imidazole derivatives, the production thereof, and the use of the same as a medicament

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)